Re: Prevention efficacy against Monkeypox Virus (MPV)

To Whom it May Concern,

In cases of emerging viral pathogens such as Monkeypox Virus, when there is no test that can be conducted to validate the efficacy of a disinfectant, the US Environmental Protection Agency utilizes their Emerging Viral Pathogens Policy to determine the expected efficacy of a disinfectant against an emerging virus. In the case of an enveloped virus such as Monkeypox Virus, the following criteria are used to determine efficacy of a disinfectant upon enactment of the Emerging Viral Pathogens Policy:

  1. The product must be a hospital or broad-spectrum disinfectant product registered with the EPA.
  2. The product must have acceptable efficacy data previously submitted to and reviewed by the Agency

    against at least one non-enveloped virus, which is considered to be more resistant to disinfectants compared to enveloped viruses such as Monkeypox Virus.

The Prevention line of disinfectants (including Prevention Ready-to-Use liquid and Wipes) fulfill these criteria and therefore can be used against Monkeypox Virus on hard, non-porous surfaces as part of a facility’s infection prevention and control protocols. Prevention Ready-to-Use liquid (EPA Reg. No. 74559-9) and Wipes (EPA Reg. No.74559-10) should be applied with a 30-second contact time. To learn more about this ongoing situation as it unfolds, please refer to the CDC’s information page at the following link:

Should you require any further information, please do not hesitate to contact us at 1-800-387-7578. Best regards,

Junette D. Tabadero

Director, Regulatory Affairs Virox Technologies Inc.


Don't forget to share this post!

Related Posts